Cognitive subgroups of affective and non-affective psychosis show differences in medication and cortico-subcortical brain networks

Katharina M Bracher[1], Afra Wohlschläger[2], Kathrin Koch[2], Franziska Knolle[2],*

[1]) Division of Neurobiology, Faculty of Biology, LMU Munich, Martinsried 82152, Germany

[2]) Department of Diagnostic and Interventional Neuroradiology, School of Medicine, Technical University of Munich, Munich, Germany

* Corresponding Author: franziska.knolle@tum.de

Conflict of Interest: None of the authors declares a conflict of interest.

Author contributions: FK, KB, AW conceptualisation; KK preprocessing of structural brain data; FK and KB formal analysis of cognitive data and clustering analysis; FK and KB writing of first draft; FK, KB, AW and KK editing and revising of manuscript.

Acknowledgement: Research using Human Connectome Project for Early Psychosis (HCP-EP) data reported in this publication was supported by the National Institute of Mental Health of the National Institutes of Health under Award Number U01MH109977. The HCP-EP 1.1 Release data used in this report came from DOI: 10.15154/1522899.

Abstract

Cognitive deficits are prevalent in individuals with psychosis and are associated with neurobiological changes, potentially serving as an endophenotype for psychosis. Using the HCP Early Psychosis dataset (n=226), we aimed to replicate cognitive subtypes (deficit, intermediate, spared) through data-driven clustering on affective and non-affective psychosis patients and controls. We explored differences between the clusters in symptom manifestation, cognition, medication, and grey matter volume, comparing patients to controls. Fuzzy K-Means clustering on PCA-selected features revealed three cognitive subgroups significantly varying in clinical symptoms and cognitive impairment, and importantly also in medication and grey matter volume in fronto-parietal and subcortical networks. The spared cluster (86% controls, 37% affective psychosis, 17% non-affective psychosis) exhibited unimpaired cognition, lowest symptoms/medication, and grey matter comparable to controls. The deficit cluster (4% controls, 10% affective psychosis, 47% non-affective psychosis) had impairments across domains, highest symptoms/medication, and pronounced grey matter alterations. The intermediate cluster (11% controls, 54% affective psychosis, 36% non-affective psychosis) showed fewer deficits than the second cluster, but similar symptoms/medication/grey matter to the first. Controlling for medication, cognitive scores correlated with grey matter changes and negative symptoms across all patients. Our findings generally emphasize the interplay between cognition, brain structure, symptoms, and medication, and specifically suggest a possible mediating role of cognition linking alterations in brain structure and symptoms, which highlights the potential of screening cognitive changes to aid in tailoring treatments and interventions.

1 Introduction

Cognitive alterations are core symptoms of psychosis [1–4], which have been described in areas of working memory [5, 6], attention [7, 8], reasoning [9, 10], decision making [11–13], salience processing [14, 15], learning (e.g., lower learning rate or increased forgetting, [16–18]) and problem solving [19, 20] and across all stages of the disease [21–25]. Cognitive deficits furthermore precede the clinical onset of psychosis [26], and predict functional outcome in later stages of the disease [27, 28], impacting employment status, independent living and social functioning [28, 29]. Although cognitive impairments are present in about 80% of patients suffering from psychotic disorders [30–32], therapeutic interventions are limited. A meta-analysis including 93 studies using different agents targeting mainly glutamatergic and cholinergic neurotransmitter systems, but also serotonin, dopamine, GABA and noradrenaline agents [33] reported a significant, although very small (g=0.10) improvement of cognition in general. However, this meta-analysis failed to find significant improvement for cognitive subdomains [33]. Cognitive training, also called cognitive remediation therapy, has produced more promising effects [34, 35]. A recent meta-analysis found that cognitive remediation showed significant small-to-moderate cognitive improvements in all domains studied (g=.19–.33) and a small improvement in function (g=.21). Furthermore, research has shown that fewer cognitive deficits and higher cognitive reserve during prodromal and first episode psychosis are generally, diagnosis-independently, associated with better functioning and recovery [36, 37]. Indicating that maintaining and improving cognitive functioning is crucial in the interventional and therapeutic processes.

Cognitive deficits in psychosis in general have been linked to alterations in the cortico-cerebellar-thalamic-cortical circuits [38]. Here, dysfunctional GABA (gamma-amino-butyric acid) inter-neurons, the main inhibitory neurons of the central nervous system, may disrupt the balance between excitatory and inhibitory processes in the cortex [39]. A recent review [25] summarizes the association between functional brain alterations and cognitive deficits in individuals at-risk for psychosis, early onset psychosis, and chronic schizophrenia. They report a clear association between altered cortical (e.g., prefrontal cortex, anterior cingulate cortex, insula) and subcortical (e.g., thalamus, striatum, hippocampus, cerebellum) brain signalling and aberrant cognition across the different stages. Further support is provided by imaging studies showing reduced gray matter volume and altered network organization which correlates with cognitive deficits, at illness onset [40, 41], early psychosis [42] and chronic schizophrenia [43].

Interestingly, psychosis patients with different diagnoses, e.g., affective vs non-affective psychosis, show varying cognitive deficits [44–46]. In a review, Barch and Sheffield [46] summarized that while the severity of cognitive impairment is stronger in non-affective compared to affective psychosis, the relative impairments across different cognitive domains are very similar. Other studies however do not differentiate between affective vs non-affective

psychosis when investigating cognitive deficits [47]. Despite these differences in cognitive alterations with regard to specific diagnoses, cognitive deficits in psychosis have been described and investigated as intermediate phenotypes [48]. In a recent study, Shafee et al.[49] pointed out that cognitive phenotypes may vary grossly depending on specific types of psychosis (e.g. affective vs non-affective), suggesting that certain domains of cognition (e.g., working memory vs face processing) may be more etiologically linked to psychosis than others. Using a K-means clustering approach in a cross-diagnostic sample, Lewandowski et al. [50] identified four cognitive subgroups combining different psychosis groups. Importantly, they identified one cognitively intact cluster including healthy controls and patients with different diagnoses, while the other three clusters were dominated by different cognitive impairment profiles [50]. A recent systematic review of data-driven identification of cognitive subtypes [51] highlighted that despite the heterogeneity of clustering methods used and cognitive domains studied, there is some commonality in the identification of a severe cognitive deficit phenotype showing deficits across multiple domains and a spared cognitive deficit phenotype with similar performances to controls. It is, however, unclear how these cognitive subtypes vary or are linked to differences in symptom expression, medication status and brain structure (i.e., grey matter volume). These open questions are however crucial in order to understand whether cognitive subtypes are clinically relevant, and could increase our mechanistic understanding of the disorder.

In the current study, we, therefore, aimed at exploring these important open questions. First, we wished to replicate three cognitive subtypes using the HCP Early Psychosis dataset (https://www.humanconnectome.org/study/human-connectome-project-for-early-psychosis, [52]) using data-driven clustering on standardized cognitive, perceptual and emotional task and score data, but no clinical data. Second, we explored whether the patients in the three clusters differed in symptom expression, cognition, medication and grey matter volume. And, third, depending on results for the first two questions, we wished to understand if symptoms, alterations in cognition and brain morphometry were associated when controlling for medication within and across the clusters.

2 Methods

2.1 Participants

We analyzed data collected by the "Human Connectome Project for Early Psychosis" (HCP-EP, [53], [54]). The HCP-EP 1.1 release (August 2021 HCP-EP Release 1.1 on NDA) contains 251 subjects consisting of 68 healthy control individuals, 57 patients with affective and 126 patients with non-affective psychosis, both patient groups were within the first three years of the onset of psychotic symptoms. The Structured Clinical Interview for DSM-5: Research Version (SCID-5-RV) ([55]) was used to confirm diagnoses of non-affective (i.e.,

schizophrenia, schizophreniform, schizoaffective, psychosis not otherwise specified, delusional disorder, brief psychotic disorder) or affective psychosis (i.e., major depression with psychosis or bipolar disorder with psychosis). Clinical symptoms were assessed using the Positive and Negative Syndrome Scale (PANSS, [56]). Disease onset for all patients was within the last five years prior to study enrollment. For a comprehensive cognitive, perceptual and emotional assessment, the NIH toolbox ([57], [58]; i.e., cognition (Picture Sequence test, Dimensional Change test, Flanker test, Picture Vocabulary test, Pattern Completion test, List Scoring test, and Oral Reading test), emotion (Self-report emotion), perception (Words in Noise, Odor Identification, and Dynamic Visual Acuity), sensory-motor functions (9-Hole Pegboard, and Grip Strength), the HCP Lifespan Measures ([59]; i.e., Delay Discounting and Penn Emotion Recognition), the WASI-II ([60]) and the Seidman Auditory Continuous Performance Test ([61]) was used. Structural brain imaging data was available for 183 of the 251 subjects. After ensuring that there were sufficient data for both, features and subjects (see description of analysis below), the analysis was performed on 226 subjects (i.e., 56 healthy controls, 52 affective psychosis group, 118 non-affective psychosis group). Demographics and clinical scores for the three groups are presented in Tab. 1. Detailed analysis of PANSS items are presented in Suppl. Fig. 1.

Table 1: Group demographics and clinical scores of final sample (N=226).

	Control	Affective	Non-Affective	Group Comparison KW-chi2/P-ch2, chi2(df), p-value
N	56	52	118	
Age - mean (std)	24.55 (4.42)	23.63 (3.85)	22.73 (3.38)	7.25 (2), <0.05
Gender - female %	33.9	57.7	30.51	11.78 (2), <0.01
PANSS total	na	44.4 (12.87)	50.21 (14.54)	12.41 (1), <0.001
PANSS positiv	na	10.04 (3.89)	12.26 (4.59)	10.99 (1), <0.001
PANSS negative	na	11.62 (4.66)	14.01 (5.59)	9.05 (1), <0.01
General psycho-pathology	na	23.40 (6.22)	25.48 (5.69)	7.12 (1), <0.01

2.2 Variable Selection and Preprocessing

Initially, all cognitive, perceptual and social/emotional functioning scores available in the HCP-EP data-set were selected, resulting in 70 variables as potentially relevant to our analysis (Suppl. Tab. 1). As covariates, we chose age, gender, socio-economic status and mother's level of education. Variables containing information of primary diagnosis for affective and non-affective psychosis, such as the Positive and Negative Symptom Score or the Clinical Assessment Interview for Negative Symptoms, as well as variables describing

medication dosage, usage or equivalent doses, were not included in the clustering analysis, but only used for subsequent analyses.

Many of the selected variables contained missing data. We therefore excluded variables when more than 10% of the entries were missing, and we excluded subjects with more than 20% missing variables (Suppl. Tab. 1). As a result, 33 of initially 70 variables remained in the data set and 226 subjects. The distribution of the remaining subjects reflected the distribution of the original data with regard to diagnosis type. For an overview of the selected variables, and group comparison, see Suppl. Tab. 2. In the final dataset used for analysis, subjects were missing a maximum of seven variables (Suppl. Tab. 4). Missing data were imputed using the mean for continuous and mode for categorical variables (e.g. demographic control variables). Since the ratio of patients and controls was not balanced, mean or mode for data imputation were calculated separately for patients and controls. Both patient groups were combined in order to minimize the bias of classical group membership (Suppl. Tab. 3).

Prior to our analysis, all continuous features and covariates were normalized using z-score normalization. Ordinal covariates such as socio-economic status and mother's education were scaled between 0 and 1, and treated gender binary.

The HCP-EP brain imaging data contain structural magnetic resonance imaging (MRI) data. We used T1-weighted structural images recorded at a 3T SIEMENS MAGNETOM Prisma scanner using a MPRAGE sequence (TR=2400ms, TE=2.22ms, FoV read=256mm, FoV phase=93.8%, flip angle=8 deg, slices per slap=208, slice thickness=0.8mm). In order to receive individual gray matter volume for structural covariance networks generated across all subjects (Suppl. Tab. 2), the structural brain data was preprocessed as described in the supplement section supplementary material 1.4 and elsewhere [62]. The structural covariance networks were used for analyses following the clustering.

2.3 Correlation and Homogeneity

To investigate correlation between all features, we performed a Pearson's correlation between all subjects' non-standardized variables. Differences between correlations between the groups were evaluated with a T-test for means of two independent samples. We then tested homogeneity between groups, using a Levene's test for equal variances between groups. Bonferroni corrections were applied.

2.4 Feature Selection

To reduce the dimensionality of our data set and at the same time keeping its maximal variance, we used a principal component analysis (PCA), which is suitable for our data type [63], and was applied to all variables and covariates. Significant principal components

were identified using a permutation test (5000 random permutations of each feature across subjects). Components which survived permutation testing were considered significant.

2.5 Fuzzy Clustering

Instead of a hard clustering approach that assumes well separated clusters and assigns each data point to only one cluster (e.g. K-Means), we used a soft clustering approach. This approach accounts for fuzzy boundaries between subgroups, and is thus better suited for overlapping subgroups [64], as would be expected for clinical groups. We, therefore, used Fuzzy K-Means clustering as described in [65]. As input to our clustering analysis, we used the dimensionality-reduced data which included demographic control variables for all three groups (i.e., controls, affective and non-affective patients). We specified the number of clusters prior to our analysis. We used a priori knowledge about the number of cognitive clusters (i.e., three different cognitive cluster were reported in the literature [51]). As a control analysis, we also used three clusters on patient data only. This analysis was used to determine influence of control subjects on the clustering, and is presented in the supplements.

Performance of the clustering analysis was determined by the ratio of the subjects of one group (healthy controls, affective psychosis group and non-affective psychosis group) in each cluster. The ratio of subjects in cluster j for group i in {controls, affective and non-affective} is defined as:

$$\text{ratio}_{i,j} = \frac{\text{number of subjects of group i in cluster j}}{\text{total number of subjects of group i}}$$

2.6 Cluster exploration

After the identification of the three clusters, we explored differences in the patients distributed over those three clusters and controls in cognitive scores, clinical scores, medication and grey matter volume. We want to point out that the control subjects were removed from each of the clusters and combined in one healthy group. Thus, a group comparison across four groups was computed. For comparing groups, we used SciPy's Kruskal-Wallis test with Dunn's test for post-hoc analyses, a Chi-square test of independence or ranked analysis of variance with Bonferroni corrected post-hoc tests. As a control analysis, we performed partial Pearson's correlations between cognitive scores, clinical scores, and grey matter volume controlled for medication across all patients, with multiple comparison corrections.

2.7 Statistical implementation

Preprocessing and data analysis was performed in Python 3.9.7. We used scikit-learn 1.0.2, SciPy 1.7.2 for all analyses and the fuzzy clustering implementation of [66]. Partial correlations were performed using the ppcor 1.1 [67]. For clustering analyses, brain data

was corrected for total intacranial volume (TIV), age and sex, using the R stats package, version 4.0.5 R [68].

3 Results

3.1 Homogeneity of data across groups

Correlations of all cognitive, perceptual and emotional functioning data revealed, that correlations were highest within controls compared to affective (T-test: t_{5838}=16.34, p<0.001) and non-affective (T-test: t_{17058}=26.03, p<0.001) patients. For non-affective patients, correlations within subjects were lowest (non-affective vs. affective patients: T-test: t_{16626}=8.47, p<0.001), indicating greatest variability. Confirming these results, highest heterogeneity was found in non-affective patients compared to controls (Levene's test for equal variance: $F_{1,174}$=187.3, p<0.001) and affective (Levene's: $F_{1,168}$=70.39, p<0.001). Controls were the most homogeneous (Levene's: $F_{1,106}$=22.34, p<0.001) (Fig. 1a).

Figure 1: **Variable correlations and dimensionality reduction of cognitive data.** **(a)** All variables (i.e., cognitive, emotional, perceptual data) correlated across subjects using Pearson correlation. Correlations within groups are displayed in squares on the diagonal, and correlations between groups are displayed in off-diagonal squares. **(b)** Variance explained by each of the PCs in % of a PCA performed on all variables and covariates across 226 subjects. The first five PCs (blue) survived permutation testing (p<0.05, 5000 permutations). Significant components captured 55.8 % of all variance. **(c)** Individual data points represent relevant variables for each subject, displayed on the first two principal components and colored according to subject group affiliation.

3.2 Feature selection using principal component analysis

During the data dimensionality reduction, we identified five significant PCs, using all data from all groups, that captured 55.8 % of total variance (Fig. 1b). Explained variance of PCAs was consistent with other symptom-reduction studies [69]. Fig. 1c illustrates the data reduction using the first two principal components. The two patient groups and the control group are predominantly distributed across the dimension of P1. However, no clear boundaries between groups could be detected. The features that explained most variance were Fluid Intelligence and Crystallized Intelligence, Total IQ, the Picture Vocabulary Test Picture vocabulary test, Oral reading recognition, Auditory attention, Working memory, WASI - Verbal comprehension, WASI - Matrix reasoning as well as DCCS - Executive functioning (Suppl. Fig. 3). To check the influence of combining patient and control data, the same analysis was performed on patients only data, which also resulted in five significant components that captured 53.7 % of all variance (p<0.05, 5000 permutations) (Suppl. Fig. 4a, b). The top ten features contributing to the explained variance were the same across both analysis - with and without controls. Those feature were taken for subsequent statistical analyses.

3.3 Group representation in the three clusters

We performed clustering on the selected features, including controls and both patient groups, with three clusters. Fig. 2a and b present the results. One cluster (cluster 0) contained 86% (48/56) of all controls and 37% (19/52) of all affective subjects. Non-affective subjects were represented only in small proportion of 17% (20/118). A mixed, second cluster (cluster 1) consisted of mostly patients, with the majority of affective individuals: 54% (28/52) of non-affective and 36% (42/118) of affective patients and only 11% (6/56) control. Most non-affective subjects were contained in the third cluster (cluster 2) with 47% (56/118) of the non-affective, and only 10% of affective patients (5/52) and 4% (2/56) of controls. (Fig. 2b).

Figure 2: **Cluster analysis: group representations and cognitive differences. (a)** Result of clustering. Cluster affiliation of each subject is displayed on the first two PCs. Colors correspond to cluster 0, 1 or 2. **(b)** Percentage of subjects of each group in each cluster. E.g. 47 % (56/118) of all non-affective subjects are in cluster 2.

3.4 Exploring cognition, symptoms, medication and gray matter volume in the clusters

To identify possible cognitive subgroups represented in the clusters, we explored cognitive scores and symptom expression for patients assigned to the clusters (see comprehensive display of statistical differences between all clusters and cognitive items in Suppl. Tab. 5). We compared cognitive scores across patients in respective clusters. Scores of control subjects were used for comparison. Patients in cluster 2 (mainly non-affective patients) showed a significant decrease in all cognitive features compared to patients assigned to other clusters, as well as controls. Patients in cluster 1, which contains 28 affective and 42 non-affective patients, showed significant decrease of Fluid Cognition, Auditory attention (%correct) and DCCS - Executive functioning compared to controls. Patients (19 affective and 20 non-affective) in cluster 0 showed most similar scores compared to control subjects, with Auditory attention (%correct) being the only score that is significantly lower compared to controls (Fig. 3c) and group comparisons are presented in Tab. 5.

Patients in cluster 2, who showed the strongest cognitive deficits and who were mainly diagnosed with non-affective psychosis, were significantly increased in PANSS total compared to patients in both, cluster 0 and 1. They were also significantly increased in PANSS positive, PANSS negative and general psychopathology compared to patients in cluster 0. Even tough patients in cluster 0 and cluster 1 did not show as a strong difference in cognitive scores, patients in cluster 1 were significantly increased in PANSS total, PANSS positive and general psychopathology compared to patients in cluster 0 (Fig. 3a) and group comparisons are presented in Tab. 5.

Further, we explored the medication status of patients within the clusters. We found that patients assigned to cluster 2 had a significantly higher Chlorpromazine equivalence dose in general and at the scanning date compared to patients in both cluster 0 and 1, and a significant increase in lifetime antipsychotic drug exposure compared to patients in cluster 1 (Fig. 3b) and group comparisons are presented in Tab. 5.

Figure 3: **Symptom expression and medication status.** **(a)** Clinical scores of affective and non-affective patient within each cluster are displayed in boxplots. Individual boxplots show data minimum, first quartile, median, third quartile, and data maximum. Individual subjects are overlaid as dots. Outliers are indicated outside the minimum or maximum. **(b)** Medication dosage and status of affective and non-affective patients within each cluster. **(c)** Cognitive score of affective and non-affective patient within each cluster are displayed and compared to all control subjects (c, light blue). The plots display the ten features contributing most to explained variance of the PCs. **(d)** Differences in three grey matter volume comparing affective and non-affective patient within each cluster are displayed and compared to all control subjects (c, light blue). NW 18 comprises the putamen and the amygdala; NW 29 comprises the paracingulate gyrus, the juxtapositional lobule, the superior parietal lobule, and the precentral gyrus; and the NW 30 comprises the superior fornatl gyrus, the frontal pole, the putamen, the postcentral gyrus and the cerebellum crus. The plots display the ten features contributing most to explained variance of the PCs. Significance is indicated as $p \leq 0.05$ (*), $p \leq 0.01$ (**) and $p \leq 0.001$ (***).

Furthermore, we explored differences in grey matter networks across the patients in the clusters and the controls. The ranked analysis of variance revealed a highly significant interaction effect $(F(87)=2.564, p=1.79e-13)$ between the patients in the three clusters and the controls (four groups) and the grey matter volume in each network (30 networks). Bonferroni corrected post-hoc analyses revealed significant differences in network 18 $(F(3,48.64)=9.32, p=0.00027)$, network 29 $(F(3,45.13)=7.8, p=6e-05)$ and network 30 $(F(3,45)=10.95, p=2e-05)$ (Fig. 3d) and group comparisons are presented in Tab. 5.

Finally, we investigated partial Pearson correlations between the ten cognitive features, the three significant grey matter volume networks, and the clinical scores, controlling for Chlorpromazine equivalent dose within each cluster and across all patients. Not with in the clusters, but across all patients we found several significant, multiple-comparison-corrected associations, see Fig. 4 and Suppl. Tab. 6.

Figure 4: **Partial correlations between brain, cognition and clinical scores.** Correcting for the equivalent dose of medication, we used Partial Pearson correlations to investigate the interaction between cognitive scores (i.e., Fluid Intelligence and Crystallized Intelligence, Total IQ, the Picture Vocabulary Test Picture vocabulary test, Oral reading recognition, Auditory attention, Working memory, WASI - Verbal comprehension, WASI - Matrix reasoning as well as DCCS - Executive functioning), brain networks (i.e., NW18, NW29, NW30), and clinical scores (i.e., PANSS total, PANSS positive, PANSS negative, General psychopathology score) across all patients independent of cluster.

Table 2: Comparison between patients in all clusters and control subjects for cognitive features that contributed most to variance, as well as medication and PANSS comparison between patients in different clusters. For the group comparison, a Kruskal–Wallis was used with a Dunn's test for pairwise comparisons (statistics and p-value displayed or ns - non significant).

Feature	group comparison	cluster 0 - 1	cluster 0 - 2	cluster 0 - controls	cluster 1 - 2	cluster 1 - controls	cluster 2 - controls
Cognitive scores							
Fluid cognition	87.649, <0.001	ns	44.3611, <0.001	ns	40.0851, <0.001	15.5651, <0.001	64.5597, <0.001
Crystallized cognition	112.1136, <0.001	ns	63.2746, <0.001	ns	84.5395, ns	ns	66.9227, <0.001
Total IQ	108.7698, <0.001	ns	57.5106, <0.001	ns	74.8416, <0.001	ns	73.4878, <0.001
Picture vocabulary test	101.079, <0.001	ns	57.5472, <0.001	ns	77.0475, <0.001	ns	59.3365, <0.001
Oral reading recognition	92.0641, <0.001	ns	47.5712, <0.001	ns	68.125, <0.001	ns	59.9688, <0.001
Auditory attention %correct	74.1838, <0.001	ns	31.6126, <0.001	11.0381, <0.01	33.1923, <0.001	12.2936, <0.01	57.8224, <0.001
Working memory	71.9626, <0.001	ns	32.4261, <0.001	ns	51.8415, <0.001	ns	50.0042, <0.001
WASI - Verbal comprehension	94.1753, <0.001	ns	51.1362, <0.001	ns	68.2115, <0.001	ns	60.9508, <0.001
WASI - Matrix reasoning	69.0919, <0.001	ns	32.4274, <0.001	ns	38.7849, <0.001	6.9518, <0.05	51.9111, <0.001
DCCS - Executive functioning	54.7055, <0.001	ns	27.6009, <0.001	ns	27.3806, <0.001	5.8383, <0.05	42.6152, <0.001
Medication status							
Lifetime Antipsychotic Drug Exposure (months)	7.2749, <0.05	ns	ns		7.2484, <0.01		
Chlorpromazine Equivalence (mg/d)	29.132, <0.001	ns	12.5926, <0.001		25.8164, <0.001		
Scan Date Chlorpromazine Equivalence (mg)	25.9395, <0.001	ns	12.1334, <0.001		22.0764, <0.001		
Positiv negative symptom score							
PANSS total	36.2777, <0.001	10.9859, <0.01	34.3385, <0.001		11.6116, <0.001		
PANSS positiv	8.9995, <0.05	4.5791, <0.05	9.1606, <0.01		ns		
PANSS negativ	38.0553, <0.001	ns	29.9315, <0.001		24.8542, <0.001		
general psychopathology	29.5877, <0.001	19.0309, <0.001	28.493, <0.001		ns		
Brain clusters							
NW 18	23.0278, <0.001	ns	7.1728, <0.05	ns	15.5068, <0.001	ns	17.3921, <0.001
NW 29	24.305, <0.001	ns	11.0358, <0.01	ns	15.5068, <0.001	ns	17.9004, <0.001
NW 30	30.4236, <0.001	ns	15.1209, <0.001	ns	17.7453, <0.001	ns	22.9485, <0.001

4 Discussion

The aim of this study was (1) to investigate cognitive subtypes using the HCP Early Psychosis dataset and data-driven clustering on standardized cognitive, perceptual and emotional task and score data, but no clinical data; to explore (2) differences in and (3) associations between cognition, symptom expression, medication and grey matter volume. Using a data driven parameter selection and clustering approach, we were able to identify three clusters that significantly differed in across cognitive deficits forming a cognitively intact cluster, an intermediately affected cluster and an cognitively affected cluster, and potentially characterise subgroups previously described in the literature [36, 50, 70–75]. Importantly, our results extend those findings, showing that patients within those clusters also differ in medication dosage, in specific grey matter brain networks and in clinical symptoms. Interestingly, across all patients but not within clusters we found that decreased grey matter volume in frontal, parietal and subcortical regions was linked to higher cognitive scores including crystallized cognition, verbal comprehension or matrix reasoning, when controlling for medication, and that decreased cognitive scores were linked to increased negative symptoms, when controlling for medication.

Using a three cluster solution on all participants (i.e., controls, affective and non-affective psychosis), allowed the identification of cognitive subtypes, which significantly varied in clinical and cognitive impairment. Patients of cluster 2, consisting of nearly 50% of the non-affective psychosis individuals, expressed the highest symptom scores across PANSS total, PANSS negative and positive and general psychopathology and impaired cognition in all domains compared to cluster 0 containing 17% of the non-affective and 37% of the affective individuals, and partially also compared to cluster 1 which consists of the majority of affective individuals and 36% of non-affective individuals. Patients in cluster 0 had the lowest symptom scores and globally spared cognitive abilities, which were similar to those of controls. Cluster 1 was intermediate, with cognitive impairments in several but not all domains and slightly increased symptoms compared to the cognitively spared cluster. This finding confirms results from Lewandowski and colleagues [50] who found a four-cluster solution to provide the best fit to their data containing three diagnostic patient groups, with one globally impaired cluster, for which cognitive deficits were associated with symptom severity and poorer functioning, one cognitively spared cluster and two intermediate clusters [50]. The overall structure of cognitive clusters identified in the present study supports findings discussed in a recent meta-analysis of data-driven identification of cognitive phenotypes in schizophrenia [51]. Green and colleagues [51] describe that what is characteristic to all cluster solutions is the presence of a cognitively spared, one or multiple intermediate and a deficit subgroup [51]. Importantly, the current study replicates three cognitive clusters using standard cognitive, perceptual and emotional assessments, selected for general cognitive screening purposes but not necessarily to detected the largest or most consistent cognitive

deficits in early stages of psychosis, suggesting generalisability among these clusters.

In addition to the differences across many cognitive domains between the patients of the clusters, we also found differences with regard to amount of medication using Chlorpromazin equivalent doses and grey matter volume in frontal, parietal and subcortical brain areas. This emphasizes the complexity of the inter-relationships of cognitive deficits, brain alteration, medication usage and symptom expression, especially when considering that the clustering is based on task and questionnaire data only, and still, differences across all domains - cognition, brain scores, medication and symptoms - have been identified. Several studies indicate an association between higher doses of medication and stronger cognitive deficits [76–78]. In a birth cohort study, for example, Husa and colleagues [76] showed that a higher lifetime dose of anti-psychotics was associated with lower cognitive performance in schizophrenia patients at the age of 43. Interestingly, a longitudinal study [77] investigating the effect of anti-psychotic treatment discontinuation showed that those individuals who did not remain on their medication after a 3.5 year follow up had improved significantly more than those who stayed on their medication even when controlling for symptom severity and cognitive scores at baseline. General non-adherence of medication use, however, does not have the same positive effect on cognition [79]. Especially, anticholinergic medication has been associated with a high cognitive burden [78], which is being supported by our results.

Changes in gray matter volume have been associated with an increased risk for psychosis and disease development [80–82], and provided the basis for good classification in a recent multicohort-study [83], as well as in earlier studies [84, 85], although classification results are inconsistent [86]. Our results show that the cluster with the strongest cognitive deficits has increased grey matter volume in three brain networks spanning fronto-parietal and subcortical areas. Across all participants and when correcting for medication we also found a negative correlation between grey matter volume and cognitive performance in several cognitive tests, including general cognition, verbal cognition and reasoning. Interestingly, grey matter volume alterations, especially reductions have been reported in association with schizophrenia [41, 87–89]. Results however depend on the specific region [90], illness stage and medication [91, 92]. Interactions between grey matter alterations and various cognitive scores have not been studied extensively. Most studies investigated cognitive alterations in specific domains (e.g., working memory) and often reported positive correlations [93–95]. Very few studies report negative correlations - increased grey matter volume being linked to reduced cognitive scores. Zhang and colleagues [96] for example showed, comparable with our results, that the performance in the Stroop Color-Word Test's Card C was negatively correlated with grey matter volumes of frontal and middle frontal brain areas. In a cohort of at-risk mental state for psychosis individuals, Koutsouleris and colleagues [97] found positive and negative correlations between grey matter volume and performance in the trail-making test, with negative correlation reported for cerebellar regions, which is comparable to what

we report in the current study. We suspect that the structural covariance networks analysis, which specifically aims at finding similarity networks between participants, and then analyses grey matter volume differences within these similar networks might contribute to the difference in directionality of the correlations. Our results however clearly demonstrate differences in the cluster containing the most strongly affected patients - clinically and cognitively. These differences reported in the literature may suggest that grey matter changes are not generally linked to cognitive changes, but rather play a mediating role. This argument would be in the same line of thought as put forward by Palaniyappan [98], stating that grey matter changes in multimodal brain regions which have a supervisory function on sensory, emotional and language processing, may link to symptom expression when occurring with functional impairments. Future studies should therefore aim at the combination of additional structural imaging data, such as structural or white matter connectivity, to complement their analysis and potentially identify underlying neuropathological mechanisms.

Our data furthermore reveals a strong link between negative symptoms and cognitive impairments. Investigating PANSS total, we found a step-wise increase in symptom severity from cluster 0 to cluster 2, with the cognitive deficit cluster 2 to show highest symptom scores. We found, also, that cluster 0, the cognitively spared cluster, showed significantly lower positive symptoms compared to cluster 1 and 2. Furthermore, the globally impaired cluster (cluster 2) revealed increased negative symptoms compared to both other clusters, and increased global psychopathology compared to the cognitively spared cluster (cluster 0), indicating that the cognitive deficits occur in those subjects with strong negative symptoms and a higher severity of general psychopathology [99]. This is in congruence with Oomen and colleagues [100] who reported three clusters based on only cognitive data with one severely cognitively impaired cluster, which showed general functioning being significantly lower compared to the patients in the other clusters. Interestingly, patients of the severely impaired cluster also showed lower general functioning scores at a trend at 6- and 12-month follow-up. Similar results were reported by Haining and colleagues [74]. Tan and colleagues [75] on the other hand did not find associations between the three cognitive clusters and symptom expression, but found that the cognitively impaired subgroup already showed worse academic performance at the level of childhood, early and late adolescence. These findings confirm the critical relevance of cognitive deficits for early detection and functional prediction [26–28, 74]. This often replicated distribution of a severely impaired cluster, indicating that early interventions based on such cluster analysis would be suitable too.

Finally, as our results confirm that patients with non-affective psychosis show stronger cognitive deficits compared to patients with affective psychosis, it is not surprising that non-affective patients are more likely to be in the intermediate and impaired subgroups. Still both patient groups are present in all clusters, with the cognitively intact subgroup consisting of 19/52 and 20/118 patients with affective and non-affective psychosis, respectively, the

intermediate group with 28/52 affective and 42/118 non-affective psychosis patients, and the cognitively impaired group with 5/52 affective and 56/118 non-affective psychosis patients. Our results indicate that clustering extends classical patient classification and diagnosis solely based on International Statistical Classification of Diseases (ICD)/Diagnostic and Statistical Manual of Mental Disorders (DSM) [101, 102] and may provide an additional characterisation of patients which may emphasise additional targets of interventions and treatment, such as cognitive remediation, especially for those individuals in the intermediate and in the deficit cluster.

This study has several limitations: Generally, K-Means [103] is a commonly used clustering algorithm that performed well on our behavioral, such as cognitive, data. Nevertheless, there are some drawbacks of this method: First, the algorithm requires a predefined number of clusters. Based on the diagnosis, data contained at least three groups. We used this prior information as basis for the specification of the number of clusters in our analysis. Based on the literature, where a spared, an impaired and an intermediate cluster are regularly detected [51] we predefined three clusters for the identification of subgroups. Identification of four or more clusters require large sample sizes in order to produce reliable and interpretable results. Our sample size does not allow this, because of the restricted number of subjects. Second, K-Means clustering does not work well with non-spherical cluster or clusters with different sizes [104]. We, therefore, also performed fuzzy K-means clustering approach which accounts for fuzzy boundaries between subgroups, and is suited for potentially overlapping subgroups [64]. The age difference between the groups might constitute another limitation of the study. However, since age was added as a covariate to all analyses, we believe that this aspect did not affect the results to a significant degree. Third, the basis of our clustering provided cognitive, perceptual and emotional test scores, which were taken from the standardised NIH toolbox ([57], [58]). Further improvement of clustering and identification of cognitive subgroups may be achieved through the selection of specific behavioral tasks and cognitive domains. Moreover, advanced analysis strategies, e.g., computational modelling may improve clustering [16, 17, 105], as it provides the opportunity to identify and mathematically differentiate behavioral parameters, which were found to be reliable and unique across individuals [106].

In conclusion, our results provide evidence for the presence of three cognitive subgroups - one cognitively intact, one intermediate and one deficit group - replicating previous findings. This study however extends those results showing that patients within those three clusters also differ with respect to current medication dosage and grey matter volume in fronto-parietal and subcortical regions. Our results therefore emphasize the complex inter-relations between cognition, symptoms, brain structure and medication, drawing attention to the pivotal role alterations in cognition as a factor for the selection of treatments and interventions.

References

[1] P. Fusar-Poli, G. Deste, R. Smieskova, S. Barlati, A. R. Yung, O. Howes, R.-D. Stieglitz, A. Vita, P. McGuire, and S. Borgwardt. "Cognitive Functioning in Prodromal Psychosis: A Meta-analysis". *Archives of General Psychiatry* 69.6 (June 2012), pp. 562–571. ISSN: 0003-990X. DOI: 10.1001/archgenpsychiatry.2011.1592.

[2] D. M. Barch and A. Ceaser. "Cognition in schizophrenia: core psychological and neural mechanisms". *Trends in cognitive sciences* 16.1 (2012), pp. 27–34.

[3] S. J. Dienel and D. A. Lewis. "Alterations in cortical interneurons and cognitive function in schizophrenia". *Neurobiology of Disease* 131 (2019), p. 104208. ISSN: 0969-9961. DOI: https://doi.org/10.1016/j.nbd.2018.06.020.

[4] M. F. Green and P. D. Harvey. "Cognition in schizophrenia: Past, present, and future". *Schizophrenia Research: Cognition* 1.1 (2014), e1–e9. ISSN: 2215-0013.

[5] A. Zanello, L. Curtis, M. B. Bâ, and M. C. Merlo. "Working memory impairments in first-episode psychosis and chronic schizophrenia". *Psychiatry research* 165.1-2 (2009), pp. 10–18.

[6] S. J. Wood, C. Pantelis, T. Proffitt, L. Phillips, G. Stuart, J.-A. Buchanan, K. Mahony, W. Brewer, D. Smith, and P. McGorry. "Spatial working memory ability is a marker of risk-for-psychosis". *Psychological medicine* 33.7 (2003), pp. 1239–1247.

[7] B. A. Cornblatt and A. K. Malhotra. "Impaired attention as an endophenotype for molecular genetic studies of schizophrenia". *American journal of medical genetics* 105.1 (2001), pp. 11–15.

[8] I. Aase, K. Kompus, J. Gisselgård, I. Joa, J. O. Johannessen, and K. Brønnick. "Language lateralization and auditory attention impairment in young adults at ultra-high risk for psychosis: A dichotic listening study". *Frontiers in psychology* 9 (2018), p. 608.

[9] P. Garety, E. Joyce, S. Jolley, R. Emsley, H. Waller, E. Kuipers, P. Bebbington, D. Fowler, G. Dunn, and D. Freeman. "Neuropsychological functioning and jumping to conclusions in delusions". *Schizophrenia Research* 150.2-3 (2013), pp. 570–574. ISSN: 09209964. DOI: 10.1016/j.schres.2013.08.035.

[10] A. O. Ermakova, N. Gileadi, F. Knolle, A. Justicia, R. Anderson, P. C. Fletcher, M. Moutoussis, and G. K. Murray. "Cost evaluation during decision-making in patients at early stages of psychosis". *Computational Psychiatry* 3 (2019), pp. 18–39. ISSN: 2379-6227.

[11] P. Sterzer, M. Voss, F. Schlagenhauf, and A. Heinz. "Decision-making in schizophrenia: A predictive-coding perspective". *NeuroImage* 190 (2019), pp. 133–143. ISSN: 1053-8119.

[12] A. O. Ermakova, F. Knolle, A. Justicia, E. T. Bullmore, P. B. Jones, T. W. Robbins, P. C. Fletcher, and G. K. Murray. "Abnormal reward prediction-error signalling in antipsychotic naive individuals with first-episode psychosis or clinical risk for psychosis". *Neuropsychopharmacology* 43.8 (2018), pp. 1691–1699.

[13] F. Brandl, F. Knolle, M. Avram, C. Leucht, I. Yakushev, J. Priller, S. Leucht, S. Ziegler, K. Wunderlich, and C. Sorg. "Negative symptoms, striatal dopamine and model-free reward decision-making in schizophrenia". *Brain* 146.2 (2023), pp. 767–777.

[14] F. Knolle, A. O. Ermakova, A. Justicia, P. C. Fletcher, N. Bunzeck, E. Düzel, and G. K. Murray. "Brain responses to different types of salience in antipsychotic naive first episode psychosis: An fMRI study". *Translational psychiatry* 8.1 (2018), pp. 1–13.

[15] J. P. Kesby, G. K. Murray, and F. Knolle. "Neural circuitry of salience and reward processing in psychosis". *Biological Psychiatry Global Open Science* (2021). ISSN: 2667-1743.

[16] F. Knolle, E. Sterner, M. Moutoussis, R. A. Adams, J. D. Griffin, J. Haarsma, H. Taverne, I. M. Goodyer, P. C. Fletcher, and G. K. Murray. "Action selection in early stages of psychosis: an active inference approach". *Journal of Psychiatry and Neuroscience* 48.1 (2023), E78–E89.

[17] M. Montagnese, F. Knolle, J. Haarsma, J. D. Griffin, A. Richards, P. E. Vertes, B. Kiddle, P. C. Fletcher, P. B. Jones, M. J. Owen, et al. "Reinforcement learning as an intermediate phenotype in psychosis? Deficits sensitive to illness stage but not associated with polygenic risk of schizophrenia in the general population". *Schizophrenia research* 222 (2020), pp. 389–396.

[18] F. Knolle, P. Sen, A. J. Culbreth, K. Koch, B. Schmitz-Koep, D. A. Guersel, K. Wunderlich, M. Avram, C. Sorg, and F. Brandl. "Modelling model-based and model-free decision-making in a transdiagnostic sample to investigate disorder-specific and transdiagnostic alterations". *medRxiv* (2023), pp. 2023–12.

[19] R. Morris, T. Rushe, P. Woodruffe, and R. Murray. "Problem solving in schizophrenia: A specific deficit in planning ability". *Schizophrenia Research* 14.3 (1995), pp. 235–246. ISSN: 0920-9964. DOI: https://doi.org/10.1016/0920-9964(94)00044-9.

[20] N. Revheim, I. Schechter, D. Kim, G. Silipo, B. Allingham, P. Butler, and D. C. Javitt. "Neurocognitive and symptom correlates of daily problem-solving skills in schizophrenia". *Schizophrenia research* 83.2-3 (2006), pp. 237–245.

[21] Y. Liu, G. Wang, H. Jin, H. Lyu, Y. Liu, W. Guo, C. Shi, J. Meyers, J. Wang, J. Zhao, et al. "Cognitive deficits in subjects at risk for psychosis, first-episode and chronic schizophrenia patients". *Psychiatry Research* 274 (2019), pp. 235–242.

[22] J. M. Sheffield, N. R. Karcher, and D. M. Barch. "Cognitive deficits in psychotic disorders: a lifespan perspective". *Neuropsychology review* 28.4 (2018), pp. 509–533.

[23] J. M. Gold and P. D. Harvey. "Cognitive deficits in schizophrenia". *Psychiatric Clinics of North America* 16.2 (1993), pp. 295–312.

[24] M. Fioravanti, O. Carlone, B. Vitale, M. E. Cinti, and L. Clare. "A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia". *Neuropsychology review* 15.2 (2005), pp. 73–95.

[25] S. Kelly, S. Guimond, A. Lyall, W. S. Stone, M. E. Shenton, M. Keshavan, and L. J. Seidman. "Neural correlates of cognitive deficits across developmental phases of schizophrenia". *Neurobiology of disease* 131 (2019), p. 104353.

[26] M. F. Green. "Impact of cognitive and social cognitive impairment on functional outcomes in patients with schizophrenia". *The Journal of clinical psychiatry* 77.suppl 2 (2016), p. 8569. ISSN: 0160-6689.

[27] G. Fervaha, H. Takeuchi, G. Foussias, M. K. Hahn, O. Agid, and G. Remington. "Achievement motivation in early schizophrenia: Relationship with symptoms, cognition and functional outcome". eng. *Early Interv Psychiatry* 12.6 (2018), pp. 1038–1044. DOI: 10.1111/eip.12405.

[28] K. Allott, P. Liu, T.-M. Proffitt, and E. Killackey. "Cognition at illness onset as a predictor of later functional outcome in early psychosis: systematic review and methodological critique". *Schizophrenia research* 125.2-3 (2011), pp. 221–235. ISSN: 0920-9964.

[29] R. Van Winkel, I. Myin-Germeys, M. De Hert, P. Delespaul, J. Peuskens, and J. Van Os. "The association between cognition and functional outcome in first-episode patients with schizophrenia: mystery resolved?" *Acta Psychiatrica Scandinavica* 116.2 (2007), pp. 119–124.

[30] A. Reichenberg, P. D. Harvey, C. R. Bowie, R. Mojtabai, J. Rabinowitz, R. K. Heaton, and E. Bromet. "Neuropsychological function and dysfunction in schizophrenia and psychotic affective disorders". *Schizophrenia bulletin* 35.5 (2009), pp. 1022–1029.

[31] A. McCleery and K. H. Nuechterlein. "Cognitive impairment in psychotic illness: prevalence, profile of impairment, developmental course, and treatment considerations". *Dialogues in clinical neuroscience* (2022).

[32] R. S. Keefe and W. S. Fenton. "How should DSM-V criteria for schizophrenia include cognitive impairment?" *Schizophrenia bulletin* 33.4 (2007), pp. 912–920.

[33] I. Sinkeviciute, M. Begemann, M. Prikken, B. Oranje, E. Johnsen, W. U. Lei, K. Hugdahl, R. A. Kroken, C. Rau, J. D. Jacobs, et al. "Efficacy of different types of cognitive enhancers for patients with schizophrenia: a meta-analysis". *NPJ schizophrenia* 4.1 (2018), pp. 1–14.

[34] A. Tripathi, S. K. Kar, and R. Shukla. "Cognitive deficits in schizophrenia: understanding the biological correlates and remediation strategies". *Clinical Psychopharmacology and Neuroscience* 16.1 (2018), p. 7.

[35] A. Vita, S. Barlati, A. Ceraso, G. Nibbio, C. Ariu, G. Deste, and T. Wykes. "Effectiveness, core elements, and moderators of response of cognitive remediation for schizophrenia: a systematic review and meta-analysis of randomized clinical trials". *JAMA psychiatry* 78.8 (2021), pp. 848–858.

[36] S. Amoretti, A. R. Rosa, G. Mezquida, B. Cabrera, M. Ribeiro, M. Molina, M. Bioque, A. Lobo, A. González-Pinto, D. Fraguas, and et al. "The impact of cognitive reserve, cognition and clinical symptoms on psychosocial functioning in first-episode psychoses". *Psychological Medicine* 52.3 (2022), pp. 526–537. DOI: 10.1017/S0033291720002226.

[37] O. Santesteban-Echarri, M. Paino, S. Rice, C. González-Blanch, P. McGorry, J. Gleeson, and M. Alvarez-Jimenez. "Predictors of functional recovery in first-episode psychosis: a systematic review and meta-analysis of longitudinal studies". *Clinical Psychology Review* 58 (2017), pp. 59–75.

[38] D. A. Lewis. "Cortical circuit dysfunction and cognitive deficits in schizophrenia–implications for preemptive interventions". *European Journal of Neuroscience* 35.12 (2012), pp. 1871–1878.

[39] M.-y. Xu and A. H. Wong. "GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia". *Acta Pharmacologica Sinica* 39.5 (2018), pp. 733–753.

[40] J. Kambeitz, L. Kambeitz-Ilankovic, C. Cabral, D. B. Dwyer, V. D. Calhoun, M. P. Van Den Heuvel, P. Falkai, N. Koutsouleris, and B. Malchow. "Aberrant functional whole-brain network architecture in patients with schizophrenia: a meta-analysis". *Schizophrenia Bulletin* 42.suppl_1 (2016), S13–S21.

[41] P. Fusar-Poli, J. Radua, P. McGuire, and S. Borgwardt. "Neuroanatomical maps of psychosis onset: voxel-wise meta-analysis of antipsychotic-naive VBM studies". *Schizophrenia bulletin* 38.6 (2012), pp. 1297–1307.

[42] T. M. Minatogawa-Chang, M. S. Schaufelberger, A. M. Ayres, F. L. Duran, E. K. Gutt, R. M. Murray, T. M. Rushe, P. K. McGuire, P. R. Menezes, M. Scazufca, et al. "Cognitive performance is related to cortical grey matter volumes in early stages of schizophrenia: a population-based study of first-episode psychosis". *Schizophrenia research* 113.2-3 (2009), pp. 200–209.

[43] N. Banaj, F. Piras, F. Piras, V. Ciullo, M. Iorio, C. Battaglia, D. Pantoli, G. Ducci, and G. Spalletta. "Cognitive and psychopathology correlates of brain white/grey matter structure in severely psychotic schizophrenic inpatients". *Schizophrenia research: cognition* 12 (2018), pp. 29–36.

[44] B. Fagerlund, A. K. Pagsberg, and R. P. Hemmingsen. "Cognitive deficits and levels of IQ in adolescent onset schizophrenia and other psychotic disorders". *Schizophrenia research* 85.1-3 (2006), pp. 30–39.

[45] M. Aas, P. Dazzan, H. L. Fisher, C. Morgan, K. Morgan, A. Reichenberg, J. Zanelli, P. Fearon, P. B. Jones, R. M. Murray, et al. "Childhood trauma and cognitive function in first-episode affective and non-affective psychosis". *Schizophrenia research* 129.1 (2011), pp. 12–19.

[46] D. M. Barch and J. M. Sheffield. "Cognitive impairments in psychotic disorders: common mechanisms and measurement". *World Psychiatry* 13.3 (2014), pp. 224–232.

[47] N. Craddock, M. C. ODonovan, and M. J. Owen. "Psychosis genetics: modeling the relationship between schizophrenia, bipolar disorder, and mixed (or "schizoaffective") psychoses". *Schizophrenia bulletin* 35.3 (2009), pp. 482–490.

[48] W. Mark and T. Toulopoulou. "Cognitive intermediate phenotype and genetic risk for psychosis". *Current Opinion in Neurobiology* 36 (2016). Neurobiology of disease, pp. 23–30. ISSN: 0959-4388. DOI: https://doi.org/10.1016/j.conb.2015.08.008.

[49] R. Shafee, P. Nanda, J. L. Padmanabhan, N. Tandon, N. Alliey-Rodriguez, S. Kalapurakkel, D. J. Weiner, R. E. Gur, R. S. Keefe, S. K. Hill, et al. "Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls". *Translational psychiatry* 8.1 (2018), pp. 1–9.

[50] K. E. Lewandowski, J. T. Baker, J. M. McCarthy, L. A. Norris, and D. Öngür. "Reproducibility of Cognitive Profiles in Psychosis Using Cluster Analysis". *Journal of the International Neuropsychological Society* 24.4 (2018), pp. 382–390. DOI: 10.1017/S1355617717001047.

[51] M. J. Green, L. Girshkin, K. Kremerskothen, O. Watkeys, and Y. Quidé. "A systematic review of studies reporting data-driven cognitive subtypes across the psychosis spectrum". *Neuropsychology Review* 30.4 (2020), pp. 446–460.

[52] K. E. Lewandowski, S. Bouix, D. Ongur, and M. E. Shenton. "Neuroprogression across the early course of psychosis". *Journal of psychiatry and brain science* 5 (2020).

[53] A. Breier, M. Shenton, D. Holt, M. Keshavan, D. Öngür, and L. Seidman. *HCP Early Psychosis 1.0 Data Release: Reference Manual 9.* Tech. rep. August. Indianapolis: Boston, MA: Brigham and Womeńs Hospital, Beth Israel Deaconess-Massachusetts Mental Health Center, McLean Hospital, Massachusetts General Hospital; 2021.

[54] K. E. Lewandowski, S. Bouix, and D. Ongur. "Neuroprogression across the Early Course of Psychosis". *Journal of Psychiatry and Brain Science* (2020), pp. 1–25. DOI: 10.20900/jpbs.20200002.

[55] M. First, J. Williams, R. Karg, and R. Spitzer. "ructured Clinical Interview for DSM-5-Research Version (SCID-5 for DSM-5, Research Version; SCID-5-RV).(2015) Arlington". *VA: American Psychiatric Association* ().

[56] S. R. Kay, A. Fiszbein, and L. A. Opler. "The positive and negative syndrome scale (PANSS) for schizophrenia". *Schizophrenia bulletin* 13.2 (1987), pp. 261–276.

[57] R. C. Gershon, M. V. Wagster, H. C. Hendrie, N. A. Fox, K. F. Cook, and C. J. Nowinski. "NIH toolbox for assessment of neurological and behavioral function". *Neurology* 80.11 Supplement 3 (2013), S2–S6.

[58] [Anonymous]. "NATIONAL INSTITUTES OF HEALTH TOOLBOX COGNITION BATTERY (NIH TOOLBOX CB): VALIDATION FOR CHILDREN BETWEEN 3 AND 15 YEARS". *MONOGRAPHS OF THE SOCIETY FOR RESEARCH IN CHILD DEVELOPMENT* 78.4 (Aug. 2013), pp. 147–149. ISSN: 0037-976X. DOI: 10.1111/mono.12040.

[59] R. C. Gur, J. Richard, P. Hughett, M. E. Calkins, L. Macy, W. B. Bilker, C. Brensinger, and R. E. Gur. "A cognitive neuroscience-based computerized battery for efficient measurement of individual differences: standardization and initial construct validation". *Journal of neuroscience methods* 187.2 (2010), pp. 254–262.

[60] D. Wechsler. "Wechsler abbreviated scale of intelligence" (1999).

[61] L. J. Seidman, E. C. Meyer, A. J. Giuliano, H. C. Breiter, J. M. Goldstein, W. S. Kremen, H. W. Thermenos, R. Toomey, W. S. Stone, M. T. Tsuang, et al. "Auditory working memory impairments in individuals at familial high risk for schizophrenia." *Neuropsychology* 26.3 (2012), p. 288.

[62] F. Knolle, S. S. Arumugham, R. A. Barker, M. W. Chee, A. Justicia, N. Kamble, J. Lee, S. Liu, A. Lenka, S. J. Lewis, et al. "A multicentre study on grey matter morphometric biomarkers for classifying early schizophrenia and parkinson's disease psychosis". *npj Parkinson's Disease* 9.1 (2023), p. 87.

[63] C. Sperber. "The use of principal component and factor analysis to measure fundamental cognitive processes in neuropsychological data". *bioRxiv* (2022). DOI: `10.1101/2021.11.10.468133`. eprint: `https://www.biorxiv.org/content/early/2022/03/19/2021.11.10.468133.full.pdf`.

[64] K. Majumdar. "Human scalp EEG processing: Various soft computing approaches". *Applied Soft Computing* 11.8 (2011), pp. 4433–4447. DOI: `https://doi.org/10.1016/j.asoc.2011.07.004.`.

[65] J. C. Bezdek, R. Ehrlich, and W. Full. "FCM: The fuzzy c-means clustering algorithm". *Computers & Geosciences* 10.2-3 (1984), pp. 191–203. DOI: `https://doi.org/10.1016/0098-3004(84)90020-7.`.

[66] M. L. D. Dias. *fuzzy-c-means: An implementation of Fuzzy C-means clustering algorithm.* May 2019. DOI: `10.5281/zenodo.3066222`.

[67] S. Kim. "ppcor: an R package for a fast calculation to semi-partial correlation coefficients". *Communications for statistical applications and methods* 22.6 (2015), p. 665.

[68] R Core Team. *R: A Language and Environment for Statistical Computing.* ISBN 3-900051-07-0. R Foundation for Statistical Computing. Vienna, Austria, 2013.

[69] J. L. Ji, M. Helmer, C. Fonteneau, J. B. Burt, Z. Tamayo, J. Demšar, B. D. Adkinson, A. Savić, K. H. Preller, F. Moujaes, F. X. Vollenweider, W. J. Martin, G. Repovš, J. D. Murray, and A. Anticevic. "Mapping brain-behavior space relationships along the psychosis spectrum". *eLife* 10 (July 2021). ISSN: 2050084X. DOI: `10.7554/eLife.66968`.

[70] K. Lewandowski, S. Sperry, B. Cohen, and D. Öngür. "Cognitive variability in psychotic disorders: a cross-diagnostic cluster analysis". *Psychological medicine* 44.15 (2014), pp. 3239–3248.

[71] M. P. Reser, K. A. Allott, E. Killackey, J. Farhall, and S. M. Cotton. "Exploring cognitive heterogeneity in first-episode psychosis: What cluster analysis can reveal". *Psychiatry Research* 229.3 (2015), pp. 819–827.

[72] J. Uren, S. M. Cotton, E. Killackey, M. M. Saling, and K. Allott. "Cognitive clusters in first-episode psychosis: Overlap with healthy controls and relationship to concurrent and prospective symptoms and functioning." *Neuropsychology* 31.7 (2017), p. 787.

[73] J. J. Crouse, A. A. Moustafa, S. E. Bogaty, I. B. Hickie, and D. F. Hermens. "Parcellating cognitive heterogeneity in early psychosis-spectrum illnesses: a cluster analysis". *Schizophrenia Research* 202 (2018), pp. 91–98.

[74] K. Haining, R. Gajwani, J. Gross, A. I. Gumley, R. A. Ince, S. M. Lawrie, F. Schultze-Lutter, M. Schwannauer, and P. J. Uhlhaas. "Characterising cognitive heterogeneity in individuals at clinical high-risk for psychosis: a cluster analysis with clinical and functional outcome prediction". *European Archives of Psychiatry and Clinical Neuroscience* 272.3 (2022), pp. 437–448.

[75] E. J. Tan, S. L. Rossell, K. L. Subotnik, J. Ventura, and K. H. Nuechterlein. "Cognitive heterogeneity in first-episode psychosis and its relationship with premorbid developmental adjustment". *Psychological Medicine* 52.16 (2022), pp. 3885–3894.

[76] A. P. Husa, J. Moilanen, G. K. Murray, R. Marttila, M. Haapea, I. Rannikko, J. H. Barnett, P. B. Jones, M. Isohanni, A. M. Remes, et al. "Lifetime antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a general population birth cohort". *Psychiatry research* 247 (2017), pp. 130–138.

[77] N. Albert, L. Randers, K. Allott, H. D. Jensen, M. Melau, C. Hjorthøj, and M. Nordentoft. "Cognitive functioning following discontinuation of antipsychotic medication. A naturalistic sub-group analysis from the OPUS II trial". *Psychological medicine* 49.7 (2019), pp. 1138–1147.

[78] Y. B. Joshi, M. L. Thomas, D. L. Braff, M. F. Green, R. C. Gur, R. E. Gur, K. H. Nuechterlein, W. S. Stone, T. A. Greenwood, L. C. Lazzeroni, et al. "Anticholinergic medication burden–associated cognitive impairment in schizophrenia". *American Journal of Psychiatry* 178.9 (2021), pp. 838–847.

[79] F. Senner, L. Hiendl, S. Bengesser, K. Adorjan, I.-G. Anghelescu, B. T. Baune, M. Budde, U. Dannlowski, D. E. Dietrich, P. Falkai, et al. "Medication adherence and cognitive performance in schizophrenia-spectrum and bipolar disorder: results from the PsyCourse Study". *Translational Psychiatry* 13.1 (2023), p. 99.

[80] R. Gallardo-Ruiz, B. Crespo-Facorro, E. Setién-Suero, and D. Tordesillas-Gutierrez. "Long-term grey matter changes in first episode psychosis: a systematic review". *Psychiatry Investigation* 16.5 (2019), p. 336.

[81] A. Vita, L. De Peri, G. Deste, and E. Sacchetti. "Progressive loss of cortical gray matter in schizophrenia: a meta-analysis and meta-regression of longitudinal MRI studies". *Translational psychiatry* 2.11 (2012), e190–e190.

[82] P. Fusar-Poli, R. Smieskova, G. Serafini, P. Politi, and S. Borgwardt. "Neuroanatomical markers of genetic liability to psychosis and first episode psychosis: a voxel-wise meta-analytical comparison". *The World Journal of Biological Psychiatry* 15.3 (2014), pp. 219–228.

[83] F. Knolle, S. S. Arumugham, R. A. Barker, M. W. Chee, A. Justicia, N. Kamble, J. Lee, S. Liu, A. Lenka, S. J. Lewis, et al. "Grey matter morphometric biomarkers for classifying early schizophrenia and PD psychosis: a multicentre study". *medRxiv* (2022).

[84] S. Iwabuchi, P. F. Liddle, and L. Palaniyappan. "Clinical utility of machine-learning approaches in schizophrenia: improving diagnostic confidence for translational neuroimaging". *Frontiers in psychiatry* 4 (2013), p. 95.

[85] H. G. Schnack, M. Nieuwenhuis, N. E. van Haren, L. Abramovic, T. W. Scheewe, R. M. Brouwer, H. E. H. Pol, and R. S. Kahn. "Can structural MRI aid in clinical classification? A machine learning study in two independent samples of patients with schizophrenia, bipolar disorder and healthy subjects". *Neuroimage* 84 (2014), pp. 299–306.

[86] S. Vieira, Q.-y. Gong, W. H. Pinaya, C. Scarpazza, S. Tognin, B. Crespo-Facorro, D. Tordesillas-Gutierrez, V. Ortiz-Garcıa, E. Setien-Suero, F. E. Scheepers, et al. "Using machine learning and structural neuroimaging to detect first episode psychosis: reconsidering the evidence". *Schizophrenia bulletin* 46.1 (2020), pp. 17–26.

[87] K. Dempster, R. Norman, J. Théberge, M. Densmore, B. Schaefer, and P. Williamson. "Cognitive performance is associated with gray matter decline in first-episode psychosis". *Psychiatry Research: Neuroimaging* 264 (2017), pp. 46–51.

[88] E. I. Ivleva, A. S. Bidesi, M. S. Keshavan, G. D. Pearlson, S. A. Meda, D. Dodig, A. F. Moates, H. Lu, A. N. Francis, N. Tandon, et al. "Gray matter volume as an intermediate phenotype for psychosis: Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP)". *American Journal of Psychiatry* 170.11 (2013), pp. 1285–1296.

[89] N. Liu, Y. Xiao, W. Zhang, B. Tang, J. Zeng, N. Hu, S. Chandan, Q. Gong, and S. Lui. "Characteristics of gray matter alterations in never-treated and treated chronic schizophrenia patients". *Translational psychiatry* 10.1 (2020), p. 136.

[90] D. C. Glahn, A. R. Laird, I. Ellison-Wright, S. M. Thelen, J. L. Robinson, J. L. Lancaster, E. Bullmore, and P. T. Fox. "Meta-analysis of gray matter anomalies in schizophrenia: application of anatomic likelihood estimation and network analysis". *Biological psychiatry* 64.9 (2008), pp. 774–781.

[91] X.-X. Shan, Y.-P. Ou, P. Pan, Y.-D. Ding, J. Zhao, F. Liu, J.-D. Chen, W.-B. Guo, and J.-P. Zhao. "Increased frontal gray matter volume in individuals with prodromal psychosis". *CNS Neuroscience & Therapeutics* 25.9 (2019), pp. 987–994.

[92] S. V. Haijma, N. Van Haren, W. Cahn, P. C. M. Koolschijn, H. E. Hulshoff Pol, and R. S. Kahn. "Brain volumes in schizophrenia: a meta-analysis in over 18 000 subjects". *Schizophrenia bulletin* 39.5 (2013), pp. 1129–1138.

[93] M. Rapado-Castro, M. Villar-Arenzana, J. Janssen, D. Fraguas, I. Bombin, J. Castro-Fornieles, M. Mayoral, A. González-Pinto, E. de la Serna, M. Parellada, et al. "Fronto-parietal gray matter volume loss is associated with decreased working memory performance in adolescents with a first episode of psychosis". *Journal of Clinical Medicine* 10.17 (2021), p. 3929.

[94] M. Picó-Pérez, R. Vieira, M. Fernández-Rodrıguez, M. A. P. De Barros, J. Radua, and P. Morgado. "Multimodal meta-analysis of structural gray matter, neurocognitive and social cognitive fMRI findings in schizophrenia patients". *Psychological Medicine* 52.4 (2022), pp. 614–624.

[95] R. C. Wolf, A. Höse, K. Frasch, H. Walter, and N. Vasic. "Volumetric abnormalities associated with cognitive deficits in patients with schizophrenia". *European Psychiatry* 23.8 (2008), pp. 541–548.

[96] Y. Zhu, F. Y. Womer, H. Leng, M. Chang, Z. Yin, Y. Wei, Q. Zhou, S. Fu, X. Deng, J. Lv, et al. "The relationship between cognitive dysfunction and symptom dimensions across schizophrenia, bipolar disorder, and major depressive disorder". *Frontiers in psychiatry* 10 (2019), p. 253.

[97] N. Koutsouleris, K. Patschurek-Kliche, J. Scheuerecker, P. Decker, R. Bottlender, G. Schmitt, D. Rujescu, I. Giegling, C. Gaser, M. Reiser, et al. "Neuroanatomical correlates of executive dysfunction in the at-risk mental state for psychosis". *Schizophrenia research* 123.2-3 (2010), pp. 160–174.

[98] L. Palaniyappan, V. Balain, and P. F. Liddle. "The neuroanatomy of psychotic diathesis: A meta-analytic review". *Journal of Psychiatric Research* 46.10 (2012), pp. 1249–1256. ISSN: 0022-3956. DOI: https://doi.org/10.1016/j.jpsychires.2012.06.007.

[99] M. Carbon and C. U. Correll. "Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia". *CNS Spectrums* 19.S1 (2014), pp. 35–53. DOI: 10.1017/S1092852914000601.

[100] P. P. Oomen, M. J. Begemann, B. A. Brand, L. de Haan, W. Veling, S. Koops, J. van Os, F. Smit, P. R. Bakker, N. van Beveren, et al. "Longitudinal clinical and functional outcome in distinct cognitive subgroups of first-episode psychosis: a cluster analysis". *Psychological Medicine* (2021), pp. 1–11.

[101] M. J. Kas, B. Penninx, B. Sommer, A. Serretti, C. Arango, and H. Marston. "A quantitative approach to neuropsychiatry: The why and the how." eng. *Neuroscience and biobehavioral reviews* 97 (Feb. 2019), pp. 3–9. ISSN: 1873-7528 (Electronic). DOI: 10.1016/j.neubiorev.2017.12.008.

[102] P. F. Hitchcock, E. I. Fried, and M. J. Frank. "Computational psychiatry needs time and context". *Annual review of psychology* 73 (2022), p. 243.

[103] J. A. Hartigan and M. A. Wong. "A K-Means Clustering Algorithm". *Journal of the Royal Statistical Society. Series C (Applied Statistics)* 28.1 (Mar. 1979), pp. 100–108. ISSN: 00359254. DOI: 10.2307/2346830.

[104] L. Ertöz, M. Steinbach, and V. Kumar. "Finding Clusters of Different Sizes, Shapes, and Densities in Noisy, High Dimensional Data". *Proceedings*. Society for Industrial & Applied Mathematics (SIAM), May 2003, pp. 47–58. DOI: 10.1137/1.9781611972733.5.

[105] Q. J. Huys, T. V. Maia, and M. J. Frank. "Computational psychiatry as a bridge from neuroscience to clinical applications". *Nature neuroscience* 19.3 (2016), pp. 404–413.

[106] A. Mkrtchian, V. Valton, and J. P. Roiser. "Reliability of Decision-Making and Reinforcement Learning Computational Parameters". *bioRxiv* (2021). DOI: 10.1101/2021.06.30.450026. eprint: https://www.biorxiv.org/content/early/2021/11/06/2021.06.30.450026.full.pdf.

[107] J. Ashburner. "A fast diffeomorphic image registration algorithm". *Neuroimage* 38.1 (2007), pp. 95–113.

[108] K. Koch, D. Rodriguez-Manrique, O. G. Rus-Oswald, D. A. Gürsel, G. Berberich, M. Kunz, and C. Zimmer. "Homogeneous grey matter patterns in patients with obsessive-compulsive disorder". *NeuroImage: Clinical* 31 (2021), p. 102727.

[109] A. Pichet Binette, J. Gonneaud, J. W. Vogel, R. La Joie, P. Rosa-Neto, D. L. Collins, J. Poirier, J. C. Breitner, S. Villeneuve, E. Vachon-Presseau, et al. "Morphometric network differences in ageing versus Alzheimer's disease dementia". *Brain* 143.2 (2020), pp. 635–649.

[110] Y. Zeighami, M. Ulla, Y. Iturria-Medina, M. Dadar, Y. Zhang, K. M.-H. Larcher, V. Fonov, A. C. Evans, D. L. Collins, and A. Dagher. "Network structure of brain atrophy in de novo Parkinsonś disease". *Elife* 4 (2015), e08440.

[111] M. Beckmann, H. Johansen-Berg, and M. F. Rushworth. "Connectivity-based parcellation of human cingulate cortex and its relation to functional specialization". *Journal of Neuroscience* 29.4 (2009), pp. 1175–1190.